Partial mastectomy using manual blunt dissection (MBD) in early breast cancer

Abstract

BackgroundBreast-preserving surgery (Bp) and sentinel lymph node biopsy (SNB) are established as standard treatment for axillary lymph node-negative early breast cancer.MethodsA surgical technique using manual blunt dissection (MBD), in which use of electrocautery, an ultrasonically activated scalpel, and ligation is minimized, is described. This involves an approach from small incisions in the axilla or areola to avoid injury to skin flaps, and with adequate mobilization of the breast, so that regardless of the tumor site, surgical wounds are not noticeable. The usefulness and tolerability of this surgical technique were examined.ResultsThis surgical technique was evaluated in 233 patients. Surgery could be performed rapidly, with a mean operative time of 67 ± 21 min and a low mean blood loss of only 35 ± 28 ml. There was little need for postoperative analgesia, and surgery was well tolerated without postoperative bleeding or wound infection.ConclusionOur proposed technique for partial mastectomy using MBD provides good curative and cosmetic results.

Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer

“…We defined clinical partial response and complete response as ‘responders’ in the objective response rate (ORR), while clinical stable disease and clinical progressive disease were evaluated as ‘non-responders’. Patients underwent surgery (i.e., total mastectomy or breast-conserving surgery) after POC (Kashiwagi et al 2015 ). The pathological therapeutic effect of POC was evaluated using resected specimens, and a pathological complete response (pCR) was defined as the complete disappearance of the invasive components of the lesion with or without intraductal components (including that in the lymph nodes) according to the National Surgical Adjuvant Breast and Bowel Project B-18 protocol (Wolmark et al 2001 ).…”

Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer

“…Patients who achieved clinically partial or complete response were categorized as “responders” in the objective response rate (ORR), while patients with clinically stable or progressive disease were defined as “non-responders”. The patients subsequently underwent mastectomy or breast-conserving surgery [19], and the pathological therapeutic effect of the POC was evaluated using the resected specimens. Pathological complete response (pCR) was defined as complete disappearance of the lesion’s invasive components, including the lymph nodes, with or without intraductal components, according to the National Surgical Adjuvant Breast and Bowel Project B-18 protocol [20].…”

Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer

“…During the first half of the POC regimen, all patients received four courses of FEC100 (500 mg/m 2 fluorouracil, 100 mg/m 2 epirubicin, and 500 mg/m 2 cyclophosphamide) every 3 weeks. During the second half of the POC regimen, 12 courses of 80 mg/m 2 paclitaxel were administered to all patients weekly, and weekly (2 mg/kg) or tri-weekly (6 mg/kg) trastuzumab was also administered in cases of HER2-positive disease [20–22]. Antitumor effects were evaluated according to the Response Evaluation Criteria in Solid Tumors [23].…”